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Abstract: 
Purpose 
To determine the prevalence of the toxic shock toxin gene (tst) and to enumerate 
circulating strains of methicillin-sensitive Staphylococcus aureus (MSSA) and 
methicillin-resistant S. aureus (MRSA) in Australian isolates collected over two 
decades.  
Methods 
Isolates were assayed using real-time PCR for mecA, nuc, 16S rRNA, 8 single 
nucleotide polymorphisms (SNPs) and for five binary genes (pvl, cna, sdrE, pUB110, 
pT181). Two real-time PCR assays were developed for tst.  
Results 
The 90 MRSA isolates belonged to CC239 (39 in 1989, 38 in 1996 and 10 in 2003), 
CC1 (2 in 2003) and CC22 (1 in 2003). The majority of the 210 MSSA isolates 
belonged to CC1 (28), CC5 (24), CC78 (23), CC15 (22) and CC45 (22). Only 18 
isolates were tst-positive and only 15 were pvl-positive. Nine MSSA isolates belonged 
to 5 binary types of ST93 including 2 pvl-positive types. 
Conclusions 
The proportion of tst-positive and pvl-positive isolates was low and no significant 
increase was demonstrated. Dominant MSSA clonal complexes were similar to those 
seen elsewhere exception for CC78. CC239 MRSA (AUS-2/3) was the predominant 
MRSA but decreased significantly in prevalence while CC22 (EMRSA-15) and CC1 
(WA-1) emerged. Genetically diverse ST93 MSSA predated the emergence of ST93-
MRSA (the Queensland clone). 
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Introduction: 
The pathogenicity of Staphylococcus aureus can in part be attributed to the production 
of pyrogenic toxins such as toxic shock toxin-1 (TSST-1) [1]. TSST-1 is a 21.9-kDa 
protein that is encoded by the S. aureus toxic shock toxin gene (tst) gene [2]. The 
release of TSST-1 into the bloodstream may give rise to a variety of severe clinical 
conditions, such as toxic shock syndrome (TSS), sudden infant death syndrome, and 
Kawasaki syndrome. The tst gene is present in up to 70% of the S. aureus strains 
isolated from patients with TSS. Without appropriate therapy, lethal shock may 
develop within 24h after the onset of symptoms. Although most cases of TSS are 
associated with tampon use, an increasing number of cases are related to localized 
infections, surgical complications and insect bites [1-4]. 
  
There has been a worldwide increase in the frequency of clusters of TSS since the 
1980s, but this has not been noted specifically in cases reported from Australia. In 
1983 the Communicable Diseases Intelligence reported 11 cases of toxic shock in 
1981, 7 in 1982 and 4 in 1983 in Australia [5]. The Therapeutic Goods Administration 
stated that between 1982 and 1994 there were 38 reports of TSS in Australia, of which 
3 cases were fatal and 10 were female non-menstrual cases [6]. In 1996 Robinson and 
Peel reported the result of 2 surveys to identify TSS cases 1990-1994. Their survey 
revealed 11 possible cases of TSS from intensive care units (ICUs) in Australia and 
New Zealand and 12 TSS cases from Victoria, Australia [7]. A search by Donovan et 
al for possible fatal cases of TSS, by reviewing records of females whose deaths were 
registered in 1978-1979, revealed that unrecognized TSS could not be excluded as the 
cause of one of the deaths [8]. A number of isolated case reports of TSS have been 
published including TSS associated with newly diagnosed type I diabetes mellitus [9] 
and TSS in a male complicated by oliguric acute renal failure [10]. Reports of shock 
associated with S. aureus infection which resembled TSS but not reported as such, 
include the death of 12 children after receiving a S. aureus contaminated diphtheria 
toxin-antitoxin mixture and a case of late-onset warfarin necrosis [11, 12]. In 2005 a 
case of menstrual TSS was reported by MacIsaac et al indicating that staphylococcus 
toxic shock syndrome is still a problem [13]. The paucity of ongoing reports on TSS 
and absence of reports indicating an increase of TSS in Australia raises the question 
of whether the TSST-1 gene is common in S. aureus in Australia. It has been 
postulated that modifications to the host population, such that the fitness of organisms 
already carrying TSST-1 genes increases, could result in an increase in TSS [14]. 
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The aims of this study were to determine the prevalence of the tst gene and to 
enumerate the circulating strains of S. aureus including methicillin-resistant S. aureus 
(MRSA) in a substantial Australian collection of isolates encompassing 1989-2003. 
 
Materials and methods: 
Selection of archival isolates 
300 S. aureus isolates collected at Princess Alexandra Hospital as part of Australian 
Group for Antimicrobial Resistance (AGAR) 1989, 1996 and 2003 national 
staphylococcal surveys were examined. The same sampling methodology was used in 
all three year groups and there was no distinction made between community- and 
healthcare-associated isolates. The isolates were from specimens submitted for 
clinical diagnosis and not for infection control screening and duplicates were excluded 
[15]. 
 
After the isolates were retrieved from storage at minus 80°C, there were 91 pure S. 
aureus isolates from 1989, 104 from 1996 and 105 from 2003.  
 
DNA extraction 
Isolates were grown on horse blood agar in air at 37°C overnight. 1 μL loop of pure 
24 hour colonies were emulsified into 250 μL water in 1.5mL simple prelabelled 
microtube and DNA extraction was performed using the MagNA Pure LC Total 
Nucleic Acid Isolation Kit on the Roche MagNA Pure instrument. 
Amplification of the 16S ribosomal DNA was used to confirm the quality of each 
DNA extract and the absence of PCR inhibitors.  
 
Detection of tst gene 
Two assays were developed for the detection of the tst gene, using the two primer sets 
previously described in the literature (Table 1). Primer sets were supplied by Sigma 
Genosys. The tst gene was detected using real-time PCR with SYBR green on the 
RotorGene 3000 (Corbett Research, Mortlake, Australia).   
The conditions of the assay were: 
50oC 2 min, 95oC 2 min, 40 cycles of 95oC 15 sec, 56oC 20 sec, 72oC 35 sec;  
Melt 72oC to 99oC at 1oC intervals. 
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The gene was considered detected if the cycle threshold (Ct) was crossed in a 
predetermined Ct interval within which all positive control strains were positive and 
all negative control strains undetected.  
 
Strain typing 
Real-time PCR assays for mecA, nuc and 16S rRNA genes were performed on all 
isolates to confirm the identity and methicillin resistance, based on publications by 
Barski et al and Unal et al.[16, 17]. 
 
Real-time PCR typing of S. aureus is based on previous publication by Huygens et al. 
[18], for single nucleotide polymorphisms (SNP) derived from the multi locus 
sequence typing (MLST) database of 7 housekeeping genes. The method involves 8 
PCRs for arcC210, tpi241 + tpi243, arcC162, gmk318, pta294, tpi36 (tpi36*C and 
tpi36*T) and pta383. It is able to distinguish between major clonal complexes (CCs) 
and is largely concordant with the population structure of S. aureus as determined by 
MLST. A single SNP-based PCR to detect aroE525G  was added to confirm the 
identity of ST93 (the Queensland clone) when the appropriate 7 SNP profile 
(TGGTTCTA)was obtained. The binary genes interrogated were pvl, cna, sdrE, 
pUB110 and pT181 according to Huygens et al [18]. The presence of the genes was 
detected using real-time PCR with SYBR green on the RotorGene 3000 (Corbett 
Research, Mortlake, Australia). The genes were considered detected if the threshold 
was crossed within the predetermined Ct. 
 
Statistical analysis 
Confidence interval calculations for proportions and chi-square analysis for 
probability estimates were performed using the Vassarstats Web Site 
(http://faculty.vassar.edu/lowry/VassarStats.html).  
 
Results: 
Prevalence of clonal complexes of MRSA and methicillin-sensitive S.  aureus (MSSA) 
SNP profiles of the isolates correlated with 21 CCs or sequence types (STs): 91 with 
CC239, 28 with CC1, 24 with CC5, 23 with CC78, 22 with CC15 and 22 with CC45. 
CC239 was the major strain for 1989 (43/91) followed by CC45 (10/91) and CC15 
(6/91). CC239 was again the major strain in 1996 (38/104), followed by CC1 (13/104) 
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and CC78 (11/104). In 2003, CC5 was predominant with 15/105, followed by both 
CC1 and CC15 with 11/105, and both CC239 and CC78 with 10/105 (Table 2).  
 
90 isolates were confirmed as MRSA and SNP profiles of the isolates correlated with 
3 CCs: 87 with CC239, 2 with CC1 (WA-1) and 1 CC22 (EMRSA-15). There were 
39 (42.9%; 95% confidence interval (CI) 33.2%-53.1%) MRSA isolates in the 1989 
collection and 38 (36.5; 95% CI 27.9%-46.1%) in 1996, all CC239 (AUS-2/3). In 
2003 there were only 13 (12.4%; 95% CI 7.4%-20.0%) MRSA isolates (P <0.0001) of 
which 10 were CC239, 2 CC1 (WA-1) and 1 CC22 (EMRSA-15). 
 
Of 210 MSSA isolates 26 (12.4%) were CC1, 24 (11.4%) CC5, 23 (11.0%) CC78, 22 
(10.5%) CC15, 22 (10.5%) CC45 and 17 (8.1%) CC30. The predominant strains for 
1989 were CC45 (10/52) and CC15 (6/52), for 1996 were CC1 (13/66) and CC78 
(11/66) and for 2003 were CC5 (15/92), CC15 (11/92) followed by CC78 (10/92). 
The yearly variation in prevalence of major clones was not statistically significant. 
Nine MSSA isolates belonged to ST93: 4 were in 1989, 2 in 1996 and 3 in 2003. Five 
binary types of ST93 were described including two in which pvl was present. Three of 
the five types including both pvl-positive types were seen in the isolates from 1989. 
Overall five MSSA isolates were pvl-positive in each year. No MRSA were pvl-
positive. 
 
Prevalence of tst positive isolates 
The tst gene was present in 18 isolates (6%; 95% CI 3.8%-9.3%) overall. The annual 
prevalence did not vary significantly (P = 0.289) with 3 (3.3%; 95% CI1.1%-9.3%) 
isolates positive in 1989, 6 (5.8%; 95% CI 2.7%-12.0%) positive in 1996 and 9 
(8.6%; 95% CI 4.6%-15.5%) in 2003. Based on the SNP type correlation, CC30 was 
predominant with 11 isolates, followed by 2 isolates correlating with CC45 and 2 with 
CC8, followed by the rest (Table 3). 
 
CC30 was the predominant strain for tst positive isolates in all three years, with 2/3 
isolates tst positive in 1989, the remaining tst positive isolate for 1989 was the sole 
isolate with a SNP profile consistent with ST67, ST198, ST395, ST426, ST479, ST66, 
ST68, or ST520. In 1996 4/6 CC30, 1/7 CC45 and 1/1 CC72 isolates were tst-positive 
and in 2003 5/9 CC30, 2/6 CC8, 1/5 CC45 and 1/3 ST93 isolates were tst positive. 
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tst positive isolates were from a variety of sites, none were from the female genital 
tract and none of the patients were considered to have TSS. There were equal numbers 
of male and female patients with isolates positive for the tst gene. Ages of patients 
ranged from 14 to 86 years. None of the tst positive isolates had the mecA or pvl gene 
detected. The binary gene results are summarised in Table 3.  
Discussion: 
TSST-1 is a superantigenic toxin encoded by the tst gene in S. aureus and is 
associated with TSS amongst various clinical diseases. Methods based on detection of 
the toxin depend on the concentration of toxin expressed and can be negatively 
influenced by various factors [19]. Detection of the tst gene by PCR can overcome 
these difficulties if a representative clinical isolate is available. In this study we have 
shown that the prevalence of tst in a substantial collection of S. aureus is low and has 
not changed significantly over two decades. This provides a plausible explanation for 
the low reportage of staphylococcal TSS in Australia. 
 
The genotyping data in this study provides a unique picture of prevalent S. aureus 
strains in Australia over two decades as previous studies have been restricted to 
MRSA or to a short time-frame [20, 21]. Detection of the binary genes and integrated 
plasmids adds further discrimination and potentially significant information on the 
prevalence of toxins of clinical interest such as tst and pvl.  
  
Among the 90 MRSA isolates CC239 MRSA (AUS-2/3) was the overall predominant 
strain and also the sole strain in 1989 and 1996. CC1 MRSA (WA-1) and CC22 
MRSA (EMRSA-15) only appeared in 2003. However, the total number of MRSA 
isolates decreased significantly in that year due to a marked decrease in CC239. The 
presence of CC239 (which has previously been shown to be synonymous with ST239-
MRSA-III) as the only MRSA clone in the 1989 and 1996 surveys is in keeping with 
previous studies. ST239-MRSA-III (also known in Australia as EA-MRSA or AUS-
2/3 MRSA) has been the dominant healthcare-associated strain of MRSA in Australia 
since the late 1970s. However, to our knowledge molecular typing of MRSA in 
Queensland by a method referrable to MLST had not been undertaken on isolations 
made prior to 2000. Our results provide further evidence of the ubiquity of this 
international epidemic clone in eastern Australia in the late 20th century.  The 
importation of  other strains of MRSA such as EMRSA-15 into Australia and the 
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emergence of still more local strains, including WA-1,  since 2000 has been described 
previously and is in keeping with our findings [15, 20]. Of 210 MSSA isolates, the 
major clones present were CC1, CC5, CC78, CC15, CC45 and CC30. Of these all but 
CC5 and CC78 were major clones present in the Oxfordshire collection [22]. 
However, the CC5 was also represented by a substantial number of isolates in that 
study but was characterised as a minor group at that time. CC78, on the other hand, 
was not present at all. Australia has been the major source of STs (6 of 18) belonging 
to this CC in the MLST database. Most registered isolates (22 of 28) have been 
MRSA [23]. 
 
MSSA isolates belonging to ST 93 were detected in each survey year. This sequence 
type is a singleton apparently unique to Australia and distinct from other lineages [23, 
24]. The MRSA clone of this sequence type was first described in Queensland in 2000 
[25]. A subsequent clinical cohort study conducted in the same region in 2004 and 
2005 identified five binary types among MSSA isolates and only one for ST93-
MRSA (a pvl-positive clone) [21]. Similarly, five binary types of ST93-MSSA were 
detected in this study. Three of these five types, including two pvl-positive types, 
were present among the 1989 isolates thus demonstrating that a diverse population of 
ST93 was present in south-east Queensland prior to the emergence of the Queensland 
clone by acquisition of SCCmec type IV.  
 
TSST-1 has been frequently associated with MSSA ST30, but recently community-
acquired and hospital acquired tst-positive MRSA belonging to ST5 and ST30 has 
been reported in Europe and Japan [26-30]. All of our tst-positive isolates were 
MSSA and the perhaps predictably the majority of these (11/18) belonged to CC30. In 
addition, the majority (11/17) of all CC30 isolates were tst positive.  
 
The number of pvl-positive isolates was surprisingly low: 15 MSSA overall (5%) with 
5 in each year group. A clinical cohort study in 2004-5 in the same region showed a 
pvl prevalence of 16% in 192 MSSA isolates [21]. In addition, the majority (55%) of 
non-multiresistant MRSA isolates in the same study were also pvl-positive thus 
suggesting that there has been an increase in the prevalence of pvl in circulating S. 
aureus.  In the current study most pvl-positive isolates belonged to CC30 (5) or ST93 
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(5), the same lineages as the major pvl-positive community-associated MRSA clones 
that have expanded over the last decade.  
 
The tst-positive isolates in this study were from a variety of sites including superficial 
sites and deep sterile sites in patients of widely varying age. While none of these 
patients had TSS this is not surprising as production and penetration of sufficient 
concentration of TSST-1 is required for development of the toxic shock syndrome 
[31] and only occurs in a subset of infections due to tst-positive strains. 
 
There have been recent overseas publications drawing attention to infection due to 
TSST-1 positive S. aureus [26, 27, 32, 33]. For example, TSST-1 has been involved 
in an outbreak of neonatal toxic shock-like exanthematous disease in a neonatal 
intensive care unit in Japan [32]. The emergence of TSST-1 positive community-
associated MRSA strains may lead higher rates of TSS among the young with 
attendant impact on infection control and empiric therapeutic strategies [26]. The 
recently reported tst-positive MRSA clones ST5 and ST30 have been associated with 
both hospital-acquired and community-acquired infections causing a variety of 
clinical syndromes, including TSS and suppurative infections. Recent overseas 
publications have reported that tst-positive MSSA strains belonging to ST1, ST8, and 
ST30, are a potential source of tst-positive CA-MRSA and that the pulsotype of tst-
positive MRSA clones have been found to differ from that of MSSA by a single band 
involving the SCCmec element. These findings suggest that the tst-positive MRSA 
clones may have emerged from their respective MSSA counterparts and has the same 
sequence type (ST5) of two pandemic nosocomial MRSA clones [27, 34]. These 
publications support the desirability for ongoing surveillance of MRSA and MSSA 
harbouring the tst gene as an aid to targeted infection control.  
 
 
 
Acknowledgements: 
Pathology Queensland Microbiology Laboratory where the project was performed. 
SERTF (Study, Education and Research Trust Fund) for providing the funding for the 
project. The Pathology Queensland Princess Alexandra Hospital Microbiology 
Laboratory for providing the stored isolates.  
 
 10
References: 
 
[1] Deurenberg RH, Nieuwenhuis RF, Driessen C, London N, Stassen FR, van 
Tiel FH, Stobberingh EE, Vink C (2005) The prevalence of the Staphylococcus 
aureus tst gene among community- and hospital-acquired strains and isolates from 
Wegener's Granulomatosis patients. FEMS Microbiol Lett 245 (1):185-189 
[2] Fraser J, Arcus V, Kong P, Baker E, Proft T (2000) Superantigens - powerful 
modifiers of the immune system. Mol Med Today 6 (3):125-132 
[3] Llewelyn M, Cohen J (2002) Superantigens: microbial agents that corrupt 
immunity. Lancet Infect Dis 2 (3):156-162 
[4] Lowy FD (1998) Staphylococcus aureus infections. N Engl J Med 339 
(8):520-532 
[5] Department of Health Australian Capital Territory (1983) Toxic shock 
syndrome (TSS) update. Communicable Disease Intelligence 83 (15):2-6 
[6] (1995) Toxic shock syndrome. Qld Nurse 14 (5):17 
[7] Priscilla Robinson MP, George Skowronski and Graham Rouch (1996) Toxic 
shock syndromes in Australia and New Zealand 1990-1994. Communicable Disease 
Intelligence 20 (15) 
[8] Donovan JW (1984) Search for possible fatal cases of toxic shock syndrome. 
Med J Aust 141 (10):646-647 
[9] Couper JJ, Kallincos N, Pollard A, Honeyman M, Prager P, Harrison LC, 
Rischmueller M (2000) Toxic shock syndrome associated with newly diagnosed type 
I diabetes. J Paediatr Child Health 36 (3):279-282 
[10] Raper RF, Ibels LS (1982) Toxic-shock syndrome in a male complicated by 
oliguric acute renal failure. Aust N Z J Med 12 (1):60-62 
[11] Goodman JS (1980) Toxic-shock syndrome and the Bundaberg disaster. N 
Engl J Med 303 (24):1417 
[12] Scarff CE, Baker C, Hill P, Foley P (2002) Late-onset warfarin necrosis. 
Australas J Dermatol 43 (3):202-206 
[13] MacIsaac CM, Page MA, Biggs BA, Visvanathan K (2005) Staphylococcal 
toxic shock syndrome: still a problem. Med J Aust 182 (12):651 
[14] Musser JM, Schlievert PM, Chow AW, Ewan P, Kreiswirth BN, Rosdahl VT, 
Naidu AS, Witte W, Selander RK (1990) A single clone of Staphylococcus aureus 
causes the majority of cases of toxic shock syndrome. Proc Natl Acad Sci U S A 87 
(1):225-229 
[15] Nimmo GR, Bell JM, Mitchell D, Gosbell IB, Pearman JW, Turnidge JD 
(2003) Antimicrobial resistance in Staphylococcus aureus in Australian teaching 
hospitals, 1989-1999. Microb Drug Resist 9 (2):155-160 
[16] Barski P, Piechowicz L, Galinski J, Kur J (1996) Rapid assay for detection of 
methicillin-resistant Staphylococcus aureus using multiplex PCR. Mol Cell Probes 10 
(6):471-475 
[17] Unal S, Hoskins J, Flokowitsch JE, Wu CY, Preston DA, Skatrud PL (1992) 
Detection of methicillin-resistant staphylococci by using the polymerase chain 
reaction. J Clin Microbiol 30 (7):1685-1691 
[18] Huygens F, Inman-Bamber J, Nimmo GR, Munckhof W, Schooneveldt J, 
Harrison B, McMahon JA, Giffard PM (2006) Staphylococcus aureus genotyping 
using novel real-time PCR formats. J Clin Microbiol 44 (10):3712-3719 
[19] Becker K, Roth R, Peters G (1998) Rapid and specific detection of toxigenic 
Staphylococcus aureus: use of two multiplex PCR enzyme immunoassays for 
amplification and hybridization of staphylococcal enterotoxin genes, exfoliative toxin 
genes, and toxic shock syndrome toxin 1 gene. J Clin Microbiol 36 (9):2548-2553 
 11
[20] Coombs GW, Nimmo GR, Bell JM, Huygens F, O'Brien FG, Malkowski MJ, 
Pearson JC, Stephens AJ, Giffard PM (2004) Genetic diversity among community 
methicillin-resistant Staphylococcus aureus strains causing outpatient infections in 
Australia. J Clin Microbiol 42 (10):4735-4743 
[21] Munckhof WJ, Nimmo GR, Carney J, Schooneveldt JM, Huygens F, Inman-
Bamber J, Tong E, Morton A, Giffard P (2008) Methicillin-susceptible, non-
multiresistant methicillin-resistant and multiresistant methicillin-resistant 
Staphylococcus aureus infections: a clinical, epidemiological and microbiological 
comparative study. Eur J Clin Microbiol Infect Dis 27 (5):355-364 
[22] Feil EJ, Cooper JE, Grundmann H, Robinson DA, Enright MC, Berendt T, 
Peacock SJ, Smith JM, Murphy M, Spratt BG, Moore CE, Day NP (2003) How clonal 
is Staphylococcus aureus? J Bacteriol 185 (11):3307-3316 
[23] http://saureus.mlst.net/. Cited 25 Nov 2008  
[24] Monecke S, Slickers P, Ehricht R (2008) Assignment of Staphylococcus 
aureus isolates to clonal complexes based on microarray analysis and pattern 
recognition. FEMS Immunol Med Microbiol 53 (2):237-251 
[25] Munckhof WJ, Schooneveldt J, Coombs GW, Hoare J, Nimmo GR (2003) 
Emergence of community-acquired methicillin-resistant Staphylococcus aureus 
(MRSA) infection in Queensland, Australia. Int J Infect Dis 7 (4):259-264 
[26] Ellington M.J. GM, East C., Ganner M.A., Warner M., Kearns A.M. (2007) 
Community-associated MRSA clone encoding toxic shock syndrome toxin 1 (TSST-
1) in England. 17th European Congress of Clinical Microbiology and Infectious 
Diseases. Blackwell Publishing, Munich, Germany 
[27] Durand G, Bes M, Meugnier H, Enright MC, Forey F, Liassine N, Wenger A, 
Kikuchi K, Lina G, Vandenesch F, Etienne J (2006) Detection of new methicillin-
resistant Staphylococcus aureus clones containing the toxic shock syndrome toxin 1 
gene responsible for hospital- and community-acquired infections in France. J Clin 
Microbiol 44 (3):847-853 
[28] Kikuchi K (2003) Genetic basis of neonatal methicillin-resistant 
Staphylococcus aureus in Japan. Pediatr Int 45 (2):223-229 
[29] Tristan A, Ferry T, Durand G, Dauwalder O, Bes M, Lina G, Vandenesch F, 
Etienne J (2007) Virulence determinants in community and hospital meticillin-
resistant Staphylococcus aureus. J Hosp Infect 65 Suppl 2:105-109 
[30] Parsonnet J, Goering RV, Hansmann MA, Jones MB, Ohtagaki K, Davis CC, 
Totsuka K (2008) Prevalence of toxic shock syndrome toxin 1 (TSST-1)-producing 
strains of Staphylococcus aureus and antibody to TSST-1 among healthy Japanese 
women. J Clin Microbiol 46 (8):2731-2738 
[31] Parsonnet J, Hansmann MA, Delaney ML, Modern PA, Dubois AM, Wieland-
Alter W, Wissemann KW, Wild JE, Jones MB, Seymour JL, Onderdonk AB (2005) 
Prevalence of toxic shock syndrome toxin 1-producing Staphylococcus aureus and the 
presence of antibodies to this superantigen in menstruating women. J Clin Microbiol 
43 (9):4628-4634 
[32] Nakano M, Miyazawa H, Kawano Y, Kawagishi M, Torii K, Hasegawa T, 
Iinuma Y, Ohta M (2002) An outbreak of neonatal toxic shock syndrome-like 
exanthematous disease (NTED) caused by methicillin-resistant Staphylococcus aureus 
(MRSA) in a neonatal intensive care unit. Microbiol Immunol 46 (4):277-284 
[33] Tierno PM, Jr. (2005) Reemergence of staphylococcal toxic shock syndrome 
in the United States since 2000. J Clin Microbiol 43 (4):2032; author reply 2032-2033 
[34] Layer F, Ghebremedhin B, Konig W, Konig B (2006) Heterogeneity of 
methicillin-susceptible Staphylococcus aureus strains at a German University Hospital 
 12
implicates the circulating-strain pool as a potential source of emerging methicillin-
resistant S. aureus clones. J Clin Microbiol 44 (6):2179-2185 
[35] Stephens AJ, Huygens F, Inman-Bamber J, Price EP, Nimmo GR, 
Schooneveldt J, Munckhof W, Giffard PM (2006) Methicillin-resistant 
Staphylococcus aureus genotyping using a small set of polymorphisms. J Med 
Microbiol 55 (Pt 1):43-51 
 
 13
Tables: 
 
Table 1: Primer sets for tst assays [1, 35] 
Assay  Primer Sequence Location 
1 
Forward TCATCAGCTAACTCAAATACATGGATT 537-563 
Reverse TGTGGATCCGTCATTCATTGTT 603-624 
2 
Forward CCCTTTGTTGCTTGCGACA 38-57 
Reverse CCCACTACTATACCAGTCTAGCAAATCC 141-170 
 
 
Table 2: SNP profiles and corresponding CC/ST for S. aureus isolates from 1989, 1996 and 2003. 
MLST correlation Profile 
1989 
n (%) 
1996 
n (%) 
2003 
n (%) 
Total 
n (%) 
CC1 
CGATAACT/ 
TGATTACT 
4 (4.4) 13 (12.5) 11 (10.5) 28 (9.3) 
CC15 CGATAACA 6 (6.6) 5 (4.8) 11 (10.5) 22 (7.3) 
CC20 CGATTACT  2 (1.9) 2 (1.9) 4 (1.3) 
CC22 CGGTTACA  1 (1)  2 (1.9) 3 (1) 
CC239 TGAAACCA 43 (47.3) 38 (36.5) 10 (9.5) 91 (30.3) 
CC25 CGGTAACA  2 (1.9) 2 (1.9) 4 (1.3)  
CC30 TGGATCCA 3 (3.3) 7 (6.7) 7 (6.7) 17 (5.7) 
CC45 CGGATCCA 10 (11) 7 (6.7) 5 (4.8)  22 (7.3) 
CC5 CGATTACA 2 (2.2) 7 (6.7) 15 (14.3) 24 (8)  
CC509 CGGTTCCA 3 (3.3) 3 (2.9) 4 (3.8) 10 (3.3) 
CC59, 121, 133 TGGTTCTA 2 (2.2)  1 (1)  3 (1) 
CC72 CGATTCCA 1 (1.1) 1 (1)  2 (1.9) 4 (1.3) 
CC78 TGATTACA 2 (2.2) 11 (10.6) 10 (9.5) 23 (7.7) 
CC8 
TGATACCA/ 
TGATAACA 
5 (5.5) 2 (1.9) 6 (5.7) 13 (4.3) 
CC80 CGGTACCA   1 (1) 1 (0.3) 
CC9 TGATAACT 1 (1.1)  3 (2.9) 4 (1.3) 
ST101, ST106, ST7, ST154, ST96, ST725 (CC121), 
ST629, ST203 (CC1) 
TGATTCCA 3 (3.3) 2 (1.9) 7 (6.7) 12 (4) 
ST351, ST52, ST182, ST356, ST138, ST625, ST49, 
ST617 (CC45), ST522, ST611, ST643, ST151, ST104, 
ST454 
TGGTTCCA  1 (1) 2 (1.9) 3 (1) 
ST583 (CC80), ST685 (CC8) TGGTACCA 1 (1.1)  1 (1) 2 (0.7) 
ST67, ST198, ST395, ST426, ST479, ST66, ST68, ST520 CGGATCTA 1 (1.1)   1 (0.3) 
ST93 TGGTTCTAG 4 (4.4) 2 (1.9) 3 (2.9) 9 (3) 
Total  91 (100) 104 (100) 105 (100) 300 (100) 
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Table 3: SNP and binary types of tst positive isolates 
MLST correlation Profile Binary gene subtype a 1989 1996 2003 Total 
CC30 TGGATCCA 01000 2 3 3 8 
  00000  1 2 3 
CC45 CGGATCCA 01100  1  1 
  01000   1 1 
CC72 CGATTCCA 00100  1  1 
CC8 TGATACCA 00001   1 1 
  00100   1 1 
ST67, ST198, ST395, ST426, 
ST479, ST66, ST68, ST520 
CGGATCTA 01100 1   1 
ST93 TGGTTCTAG 01000   1 1 
Total  
 
3 6 9 18 
a pvl/ cna/ sdrE/ puB110/ pT181 
 
